Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction

Aligos Therapeutics, Inc.

2024-Q3 EPS reported -$7.84 revenue$3,005,000

Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.
Cash & investments $74.9M, down from $135.7M at Dec 31, 2023; runway through end of 2025.
MASH candidate ALG-055009 achieved placebo-adjusted median relative liver fat reduction up to 46.2% at Week 12; favorable tolerability.
CHB candidate ALG-000184 progressing to Phase 2 next year; FDA and China NMPA agree on primary endpoint.
COVID protease inhibitor ALG-097558 to begin externally funded clinical studies in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.